All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.83 [0.43 ; 1.59 ] Kalil (ACTT-3), 2021, O’Donnell, 2021, PlasmAr, 2020 3 41% 1,525 low not evaluable death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lopardo, 2021 0.57 [0.24; 1.37]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.75 [0.46 ; 1.21 ] Kalil (ACTT-3), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020 4 22% 1,767 low not evaluable deaths (time to event analysis only)detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
1.08 [0.59 ; 1.97 ] Kalil (ACTT-3), 2021, PlasmAr, 2020 2 0% 1,303 low not evaluable clinical improvementdetailed results Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
1.03 [0.88 ; 1.19 ] Kalil (ACTT-3), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020 4 13% 1,766 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
1.01 [0.79 ; 1.29 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical improvement (28-day)detailed results O’Donnell, 2021 1.38 [0.73; 2.61]
1.38 [0.73 ; 2.61 ] O’Donnell, 2021 1 0% 223 NA not evaluable clinical improvement (time to event analysis only)detailed results Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.02 [0.91 ; 1.13 ] Kalil (ACTT-3), 2021, O’Donnell, 2021, PlasmAr, 2020 3 0% 1,526 moderate not evaluable mechanical ventilationdetailed results O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
1.03 [0.53 ; 2.00 ] O’Donnell, 2021, PlasmAr, 2020 2 0% 556 low not evaluable ICU admissiondetailed results Lopardo, 2021 0.67 [0.35; 1.28]
0.67 [0.35 ; 1.28 ] Lopardo, 2021 1 0% 241 NA not evaluable serious adverse eventsdetailed results O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
0.95 [0.44 ; 2.05 ] O’Donnell, 2021, PlasmAr, 2020 2 70% 552 low not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 22:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
